Novo Nordisk A/S
NVO
$65.77
$0.921.42%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.71% | 27.24% | 22.55% | 1.92% | 29.58% |
| Total Depreciation and Amortization | 71.93% | -87.76% | -14.08% | 42.66% | 26.81% |
| Total Amortization of Deferred Charges | -- | 18.52% | -- | -- | -- |
| Total Other Non-Cash Items | 316.98% | -514.56% | 503.01% | 63.65% | -119.90% |
| Change in Net Operating Assets | -65.65% | 91.02% | -197.39% | 323.85% | 4.96% |
| Cash from Operations | 66.44% | 27.50% | 8.01% | 74.52% | -51.48% |
| Capital Expenditure | -53.45% | -69.44% | -109.82% | -75.90% | -82.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.40% | 218.96% | -19.56% | -178.06% | 742.85% |
| Cash from Investing | -263.42% | -513.58% | -59.27% | -120.49% | 160.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,695.58% | -21.97% | -103.83% | -1,254.69% | 33.68% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 51.06% | 23.26% | 60.84% | 15.57% | 45.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -19.67% | -- | -17.08% | -- | -57.38% |
| Other Financing Activities | 402.67% | -- | -- | -57.03% | 57.03% |
| Cash from Financing | 120.02% | 460.47% | 6.38% | 230.87% | -29.29% |
| Foreign Exchange rate Adjustments | -289.35% | 439.62% | -184.00% | 163.81% | 116.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 379.58% | -164.33% | -49.03% | 591.74% | -457.13% |